Potential Biomarker and Therapeutic Tools for Pathological Cardiac Hypertrophy and Heart Failure: Extracellular Vesicles. [PDF]
Sun J, Zhou D, Cheng M.
europepmc +1 more source
Novel model of cardiac hypertrophy with cardiorenal dysfunction. [PDF]
de Almeida Silva A +15 more
europepmc +1 more source
Therapeutic Modulation of Mitophagy by Cafestol in Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis. [PDF]
Hao WR +7 more
europepmc +1 more source
Sodium-myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice. [PDF]
Marino A +18 more
europepmc +1 more source
RBMS1 orchestrates cardiac hypertrophy by facilitating CTTN splice-switching and sarcomere dynamics. [PDF]
Li L +19 more
europepmc +1 more source
Mitophagy in Hypertensive Cardiac Hypertrophy: Mechanisms and Therapeutic Implications. [PDF]
Li S, Li X.
europepmc +1 more source
RMC-6272, a selective third-generation bi-steric mTORC1 inhibitor, improves cardiac function in pressure overload-induced cardiac hypertrophy. [PDF]
Rogge M +8 more
europepmc +1 more source
Breast cancer susceptibility gene 2 upregulation alleviated cardiac hypertrophy in angiotensin II-treated mice. [PDF]
Liu K +5 more
europepmc +1 more source
Type-1 Ryanodine Receptor Plays an Important Role in Cardiac Hypertrophy and Heart Failure by Increasing Type-2 Ryanodine Receptor-Mediated Calcium Release. [PDF]
Wang YX +6 more
europepmc +1 more source

